within Pharmacolibrary.Drugs.ATC.L;

model L01EA06
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.41,
    Cl             = 0.0003083333333333333,
    adminDuration  = 600,
    adminMass      = 40 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.13,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.006,
    Tlag           = 10.200000000000001,            
    Vdp             = 0.166,
    k12             = 106,
    k21             = 106
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L01EA06</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Asciminib is an orally active, first-in-class, allosteric inhibitor of BCR-ABL tyrosine kinase, used in the treatment of chronic myeloid leukemia (CML) in patients with Philadelphia chromosome-positive (Ph+) CML who have been previously treated with other tyrosine kinase inhibitors. It is approved for use in several countries and is indicated for adult patients with CML in the chronic phase.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult volunteers and CML patients after oral administration.</p><h4>References</h4><ol><li><p>Hoch, M, et al., &amp; Hourcade-Potelleret, F (2022). Pharmacokinetics of asciminib in the presence of CYP3A or P-gp inhibitors, CYP3A inducers, and acid-reducing agents. <i>Clinical and translational science</i> 15(7) 1698–1712. DOI:<a href=\"https://doi.org/10.1111/cts.13285\">10.1111/cts.13285</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/35616006/\">https://pubmed.ncbi.nlm.nih.gov/35616006</a></p></li><li><p>Cortes, JE, et al., &amp; Nicolini, FE (2025). Vodobatinib for patients with Philadelphia chromosome-positive chronic myeloid leukaemia resistant or intolerant to multiple lines of previous therapy: an open-label, multicentre, phase 1/2 trial. <i>The Lancet. Haematology</i> 12(3) e201–e213. DOI:<a href=\"https://doi.org/10.1016/S2352-3026(24)00354-5\">10.1016/S2352-3026(24)00354-5</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/39929221/\">https://pubmed.ncbi.nlm.nih.gov/39929221</a></p></li><li><p>Shen, Y, et al., &amp; Xu, RA (2024). Effects of the antitumor drugs adagrasib and asciminib on apixaban metabolism in vitro and in vivo. <i>Chemico-biological interactions</i> 399 111146–None. DOI:<a href=\"https://doi.org/10.1016/j.cbi.2024.111146\">10.1016/j.cbi.2024.111146</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/39002878/\">https://pubmed.ncbi.nlm.nih.gov/39002878</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L01EA06;
